Patient Search

This is a Phase 2, open-label, parallel 3-cohort, multicenter study to evaluate the safety
and preliminary clinical activity of treatment combinations with and without chemotherapy in
participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal
adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel,
works in participants with relapsed/refractory follicular lymphoma

This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized
anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with
nivolumab or standard of care. It is being tested against advanced and/or metastatic solid
tumors including gastric, gastroesophageal junction, pancreatic cancers.

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an
engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally
occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101
will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a
monotherapy or in combination with other anticancer agents.

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell
activation signals to specific receptors on cancer cells. The study will occur in two phases.
The first phase will be a dose escalation phase, enrolling patients with various types of
solid tumors that express human epidermal growth factor receptor 2 (HER2). Two combination
therapy cohorts will be opened for enrollment, DF1001 + nivolumab and DF1001 + Nab
paclitaxel. The second phase will include a dose expansion using the best dose selected from
the first phase of the study. Multiple cohorts will be opened with eligible patients having
either selected solid tumors, or solid tumors expressing high levels of HER2.

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess
ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute
myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue
in patients with NPM1-m AML.

This phase I trial investigates the side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), with a specific focus on small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding BAY 1895344 to irinotecan or topotecan may help to slow the growth of tumors for longer than seen with those drugs alone.

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to
determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy
(HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab
(EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.

The study is enrolling in the dose expansion arms.

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara)
with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd)
or daratumumab SC in combination with bortezomib and dexamethasone (DVd).

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025
in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of
systemic therapy